The effects of adipose-derived multipotent mesenchymal stromal cells transplantation on locomotor activity and function of the sciatic nerve in mice with peripheral neuropathy

Home/2020, Vol. 8, No. 2/The effects of adipose-derived multipotent mesenchymal stromal cells transplantation on locomotor activity and function of the sciatic nerve in mice with peripheral neuropathy

Cell and Organ Transplantology. 2020; 8(2):159-165.
DOI: 10.22494/cot.v8i2.111

The effects of adipose-derived multipotent mesenchymal stromal cells transplantation on locomotor activity and function of the sciatic nerve in mice with peripheral neuropathy

Rubtsov V.1, Govbakh I.2, Ustymenko A.3,4, Kyryk V.3,4, Tsupykov O.3,5

  • 1Educational and Scientific Centre “Institute of Biology”, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine
  • 2Kharkiv Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine, Kharkiv, Ukraine
  • 3State Institute of Genetic and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
  • 4D. F. Chebotarev State Institute of Gerontology of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
  • 5Bogomoletz Institute of Physiology of the National Academy of Sciences of Ukraine, Kyiv, Ukraine

The Charcot-Marie-Tooth disease type 1A (CMT1A) is one of the most common hereditary motor-sensory peripheral neuropathies, which is caused by demyelination of motor and sensory nerve fibers and leads to nerve dysfunction. There are currently no effective treatments for hereditary neuropathies, but recent studies indicate a number of potentially effective therapeutic agents, including multipotent mesenchymal stromal cells (MMSCs).
The purpose of the study was to evaluate the effect of adipose-derived MMSCs (ADSCs) transplantation on locomotor activity and sciatic nerve function of transgenic mice with peripheral neuropathy.
Materials and methods. The transgenic B6.Cg-Tg(PMP22)C3Fbas/J mice with peripheral neuropathy were injected intramuscularly with MMSCs, which were isolated from the adipose tissue of FVB-Cg-Tg(GFPU) mice transgenic by GFP. Locomotor activity of experimental animals was investigated in dynamics in 2, 4, 6, 8 and 10 weeks using the behavioral balance beam test. The functions of the sciatic nerve were analyzed according to the footprint test by calculating the sciatic functional index (SFI).
Results. For 2-10 weeks in animals with neuropathy, disease progression was observed, which was expressed in a growing increase in the number of hindlimb paw slips from the beam and the latency to cross the beam. SFI in animals of this group decreased and at the 10th week it was -47.0 ± 2 units.
In contrast, from the 2nd week of the experiment, mice with neuropathy after ADSCs transplantation performed 20 % fewer paw slips and spent 11 % less time in the balance beam test compared to animals without cell transplantation. In the same period, there was an increase in the SFI up to -30.2 ± 2 against -34.6 ± 0.9, respectively. On the 10th week after ADSCs injection, the SFI value was -10.1 ± 2.3 units and correlated with a decrease in the number of foot slips and the time to cross the beam.
Conclusions. ADSCs transplantation improves the sciatic functional index and fine locomotor skills in mice with peripheral neuropathy. ADSCs have the potential to be an effective therapeutic agent in the treatment of peripheral neuropathy at Charcot-Marie-Tooth disease type 1A.

Key words: adipose-derived multipotent mesenchymal stromal cells; demyelination; peripheral neuropathy; sciatic functional index

Full Text PDF (eng) Full Text PDF (ua)

1. Boutary S., Echaniz-Laguna A., Adams D., Loisel-Duwattez J., Schumacher M., Massaad C., et al. Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: the past, the present and the future. Transl Res. 2021. 227. P. 100-111. doi: 10.1016/j.trsl.2020.07.006.
2. Birouk N., Gouider R., Le Guern E., Gugenheim M., Tardieu S., Maisonobe T., et al. Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain. 1997. 120, № 5. P. 813-23.
3. Lee S., Amici S., Tavori H., Zeng W. M., Freeland S., Fazio S., et al. PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts. J Neurosci. 2014. 34, № 48. P. 16140-52.
PMid:25429154 PMCid:PMC4244477
4. Marinko J. T., Carter B. D., Sanders C. R. Direct relationship between increased expression and mistrafficking of the Charcot-Marie-Tooth-associated protein PMP22. J Biol Chem. 2020. 295, № 34. P. 11963-70.
PMid:32647009 PMCid:PMC7443497
5. Vanoye C. G., Sakakura M., Follis R. M., Trevisan A. J., Narayan M., Li J., et al. Peripheral myelin protein 22 modulates store-operated calcium channel activity, providing insights into Charcot-Marie-Tooth disease etiology. J Biol Chem. 2019. 294, № 32. P. 12054-65.
PMid:31213528 PMCid:PMC6690708
6. Morena J., Gupta A., Hoyle J. C. Charcot-Marie-Tooth: From molecules to therapy. Int J Mol Sci. 2019. 20, № 14. P. 1-15.
PMid:31336816 PMCid:PMC6679156
7. Zhao H. T., Damle S., Ikeda-Lee K., Kuntz S., Li J., Mohan A., et al. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. J Clin Invest 2018. 128, № 1. P. 359-68.
PMid:29202483 PMCid:PMC5749515
8. Sociali G., Visigalli D., Prukop T., Cervellini I., Mannino E., Venturi C., et al. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. Neurobiol Dis. 2016. 95. P. 145-57. doi: 10.1016/j.nbd.2016.07.017.
9. Mazini L., Rochette L., Amine M., Malka G. Regenerative capacity of adipose derived stem cells (ADSCs), comparison with mesenchymal stem cells (MSCs). Int J Mol Sci. 2019. 20, № 10. P. 1-30.
PMid:31121953 PMCid:PMC6566837
10. Zhou L. N., Wang J. C., Zilundu P. L. M., Wang Y. Q., Guo W. P., Zhang S. X., et al. A comparison of the use of adipose-derived and bone marrow-derived stem cells for peripheral nerve regeneration in vitro and in vivo. Stem Cell Res Ther. 2020. 11, № 1. P. 153. doi: 10.1186/s13287-020-01661-3.
PMid:32272974 PMCid:PMC7147018
11. Si Z., Wang X., Sun C., Kang Y., Xu J., Wang X., et al. Adipose-derived stem cells: Sources, potency, and implications for regenerative therapies. Biomed Pharmacother. 2019. 114. P. 108765.
12. Ustymenko A., Kyryk V., Lutsenko T., Tsupykov O., Butenko G. Morphofunctional properties of adipose-derived multipotent mesenchymal stromal cells in vitro in ovariectomized mice of different ages. Cell Organ Transplant. 2019. 7, № 2. P. 158-67. doi:10.22494/cot.v7i2.102
13. Dominici М., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006. 8, № 4. Р. 315-317.
14. Joseph S., Vingil S.l, Jahn O., Fledrich R., Werner H. B., Katona I., et al. Myelinating glia-specific deletion of Fbxo7 in mice triggers axonal degeneration in the central nervous system together with peripheral neuropathy. J Neurosci. 2019. 39, № 28. P. 5606-26. DOI: 10.1523/JNEUROSCI.3094-18.2019
PMid:31085610 PMCid:PMC6616290
15. Inserra M. M., Bloch D. A, Terris D. J. Functional indices for sciatic, peroneal, and posterior tibial nerve lesions in the mouse. Microsurgery. 1998. 18, № 2. P. 119-24. doi: 10.1002/(sici)1098-2752(1998)18:2<119::aid-micr10>;2-0.<119::AID-MICR10>3.0.CO;2-0
16. Xiaoxuan L., Xiaohui D., Yingshuang Z., Dongsheng F. Clinical and genetic diversity of PMP22 mutations in a large cohort of Chinese patients with Charcot-Marie-Tooth disease. Front Neurol. 2020. 11. P. 630. doi: 10.3389/fneur.2020.00630.
PMid:32719652 PMCid:PMC7347970
17. Bain J. R., Mackinnon S. E., Hunter D. A. Functional evaluation of complete sciatic, peroneal, and posterior tibial nerve lesions in the rat. Plast Reconstr Surg. 1989. 83, № 1. P. 129-38. doi: 10.1097/00006534-198901000-00024.
18. Xing X., Han S., Cheng G., Ni Y., Li Z., Li Z. Proteomic analysis of exosomes from adipose-derived mesenchymal stem cells: a novel therapeutic strategy for tissue Injury. Biomed Res Int. 2020. 2020. P. 6094562. doi: 10.1155/2020/6094562.
PMid:32190672 PMCid:PMC7073480
19. Redondo-Castro E., Cunningham C., Miller J., Martuscelli L., Aoulad-Ali S., Rothwell N. J., et al. Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro. Stem Cell Res Ther. 2017. 8, № 1. P. 79. doi: 10.1186/s13287-017-0531-4.
PMid:28412968 PMCid:PMC5393041
20. Harrell C., Fellabaum C., Jovicic N., Djonov V., Arsenijevic N., Volarevic V. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome. Cells. 2019. 8, № 5. P. 467.
PMid:31100966 PMCid:PMC6562906

Rubtsov V, Govbakh I, Ustymenko A, Kyryk V, Tsupykov O. The effects of adipose-derived multipotent mesenchymal stromal cells transplantation on locomotor activity and function of the sciatic nerve in mice with peripheral neuropathy. Cell Organ Transpl. 2020; 8(2):159-165. doi:10.22494/cot.v8i2.111

Creative Commons License
Is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.